Anticancer agent 314 

Anticancer agent 314 is a multi-target anticancer agent with tubulin polymerization inhibitory activity (IC₅₀ = 6.35 μM) and human carbonic anhydrase IX (K_i = 27.1 nM) and XII (K_i 20.9 = nM) inhibitory activity. Anticancer agent 314 binds to the colchicine-binding pocket of tubulin and inhibits tumor-associated carbonic anhydrase isoforms via zinc coordination within enzyme active sites. Anticancer agent 314 induces G2/M phase cell cycle arrest, apoptosis via p53-dependent signaling, and broad-spectrum antiproliferative activity across multiple cancer cells. Anticancer agent 314 can be used for the research of cancer, such as leukemia, melanoma, ovarian cancer^[1].

Anticancer agent 314 (Compound 13n) potently inhibits the recombinant human tumor-associated carbonic anhydrase isoforms hCA IX (K_i = 27.1 nM) and hCA XII (K_i = 20.9 nM)^[1].
Anticancer agent 314 (1.5-100 μM) potently inhibits cell-free tubulin polymerization with an IC₅₀ of 6.35 μM^[1].
Anticancer agent 314 (0.01-100 μM) exhibits broad-spectrum antiproliferative activity across the NCI-60 human tumor cell line panel, with GI₅₀ values ranging from 2.48 to 31.00 μM^[1].
Anticancer agent 314 has low cytotoxicity against WI-38 normal human lung fibroblasts, with an IC₅₀ of 68.62 μM^[1].
Anticancer agent 314 (6.35 μM; 24 h) potently arrests MCF-7 human breast cancer cells in the G2/M phase of the cell cycle, increasing the G2/M population to 31.97%^[1].
Anticancer agent 314 (6.35 μM; 24 h) induces robust apoptosis in MCF-7 human breast cancer cells, increasing the total apoptotic population to 24.68%^[1].
Anticancer agent 314 (6.35 μM; 24 h) activates the p53-dependent apoptotic pathway in MCF-7 human breast cancer cells, increasing p53, Bax, and activated caspase-7 levels while reducing Bcl-2 levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

460.47

C₂₂H₁₆N₆O₄S

CC1=NN2C(C3=CC4=C(OC3=O)C=CC=C4)=CC=NC2=C1/N=N/C5=CC=C(C=C5)S(N)(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Elkotamy MS, et al. Multi-target pyrazolopyrimidine-coumarin derivatives as potent CA IX/XII and tubulin polymerization inhibitors: Design, synthesis, and biological evaluation. Eur J Med Chem. Published online March 20, 2026.  [Content Brief]